Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Juan‐Manuel Hernandez‐Martinez"'
Autor:
Juan-Manuel Hernandez-Martinez, Alberto Guijosa, Diana Flores‐Estrada, Graciela Cruz-Rico, Jenny Turcott, Norma Hernández-Pedro, Enrique Caballé‐Perez, Andrés F. Cardona, Oscar Arrieta
Publikováno v:
JCO Global Oncology, Iss 10 (2024)
PURPOSETargeted therapies are indicated for patients with non–small cell lung cancer (NSCLC) and driver tumor mutations. However, real-world studies on the survival benefits of these agents are limited. This study aimed to evaluate the effect of ta
Externí odkaz:
https://doaj.org/article/db598575d1ba461c87cca042bc7cbf00
Autor:
Salvador Gutierrez Torres, Federico Maldonado Magos, Jenny G. Turcott, Juan‐Manuel Hernandez‐Martinez, Bernardo Cacho‐Díaz, Andrés F. Cardona, Aida Mota‐García, Francisco Lozano Ruiz, Maritza Ramos‐Ramirez, Oscar Arrieta
Publikováno v:
Cancer Medicine, Vol 12, Iss 1, Pp 146-158 (2023)
Abstract Background Most studies evaluating factors associated with the survival of patients with brain metastases (BM) have focused on patients with newly diagnosed BM. This study aimed to identify prognostic factors associated with survival after b
Externí odkaz:
https://doaj.org/article/d165a5944bf64f57bdbca148ab5cf741
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Salvador Gutierrez Torres, Federico Maldonado Magos, Jenny G. Turcott, Juan‐Manuel Hernandez‐Martinez, Bernardo Cacho‐Díaz, Andrés F. Cardona, Aida Mota‐García, Francisco Lozano Ruiz, Maritza Ramos‐Ramirez, Oscar Arrieta
Publikováno v:
Cancer Medicine. 12:146-158
Most studies evaluating factors associated with the survival of patients with brain metastases (BM) have focused on patients with newly diagnosed BM. This study aimed to identify prognostic factors associated with survival after brain re-irradiation
Autor:
Bernardo Cacho-Díaz, Laura D. Cuapantécatl, Ytel J. Garcilazo-Reyes, Luis Cabrera-Miranda, Juan-Manuel Hernandez-Martinez, Oscar Arrieta
Publikováno v:
Oncology. 100:542-554
Introduction: Therapeutic advances have increased the survival of non-small-cell lung cancer (NSCLC) patients as well as the lifetime risk of being diagnosed with brain metastases (BM). Although BM have historically been associated with poor prognosi
Autor:
Antonio Bahena-González, Edgar Montes-Servín, Oscar Arrieta, Andrés F. Cardona, Diego Díaz-García, Luis Lara-Mejía, David Heredia, Juan-Manuel Hernandez-Martinez, Dolores L. Mendoza-Oliva, Camilo Molina-Romero
Publikováno v:
Cancer biomarkers : section A of Disease markers. 32(2)
BACKGROUND: Few trials have evaluated the utility of liquid biopsies to detect epidermal growth factor receptor mutations (EGFRm) at the time of response evaluation and its association with the clinical characteristics and outcomes of non-small-cell
Autor:
Juan-Manuel, Hernandez-Martinez, Roberto, Sánchez-Reyes, J G, De la Garza-Salazar, Oscar, Arrieta
Publikováno v:
Advances in experimental medicine and biology. 1168
Omics technologies have revolutionised fundamental and medical research. Oncology is perhaps the field where these technologies have been most rapidly adopted and where they have had their biggest impact, dramatically transforming clinical practice g
Publikováno v:
Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics ISBN: 9783030240998
Omics technologies have revolutionised fundamental and medical research. Oncology is perhaps the field where these technologies have been most rapidly adopted and where they have had their biggest impact, dramatically transforming clinical practice g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9413a64830325b5476deb6daebf84682
https://doi.org/10.1007/978-3-030-24100-1_5
https://doi.org/10.1007/978-3-030-24100-1_5
Autor:
Feliciano Barron-Barron, Edgar Vergara, Zyanya Lucia Zatarain-Barrón, Juan-Manuel Hernandez-Martinez, Oscar Arrieta
The development of immunotherapeutic agents for oncology is based on the insight that tumor development and progression is highly dependent on the ability of tumor cells to avoid immune recognition and destruction. Numerous immunomodulatory alteratio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a540c835537508b7558a998ead0881b
https://europepmc.org/articles/PMC6344701/
https://europepmc.org/articles/PMC6344701/
Autor:
Zyanya Lucia Zatarain-Barrón, Juan-Manuel Hernandez-Martinez, Andrés F. Cardona, Oscar Arrieta
Publikováno v:
Repositorio U. El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
Immunotherapy with programmed death 1 (PD-1)- and programmed death-ligand 1 (PD-L1)-targeted monoclonal antibodies has dramatically changed the therapeutic and prognostic landscape for several types of malignancy. PD-1 and PD-L1 are immune checkpoint
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db1c3a5e45bfc57488aee02cfbf6f537
https://europepmc.org/articles/PMC6297543/
https://europepmc.org/articles/PMC6297543/